DOP2011000016A - Composiciones y metodos de uso para anticuerpos terapeuticos - Google Patents
Composiciones y metodos de uso para anticuerpos terapeuticosInfo
- Publication number
- DOP2011000016A DOP2011000016A DO2011000016A DO2011000016A DOP2011000016A DO P2011000016 A DOP2011000016 A DO P2011000016A DO 2011000016 A DO2011000016 A DO 2011000016A DO 2011000016 A DO2011000016 A DO 2011000016A DO P2011000016 A DOP2011000016 A DO P2011000016A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- antibodies
- compositions
- methods
- therapeutic antibodies
- baffr
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 abstract 3
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Anticuerpos que se enlazan específicamente al receptor de BAFF (BAFFR). De una manera más específica, anticuerpos que son antagonistas del BAFFR, con actividad consumidora de células-B ¡n vivo, y composiciones y métodos de uso para estos anticuerpos con el fin de tratar los trastornos patológicos que puedan ser tratados mediante la aniquilación o el consumo de las cétulas-B, tales como lupus eritematoso sistémico o artritis reumatoide, u otras enfermedades autoinmunes o linfomas, leucemias, y mielomas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08160671 | 2008-07-17 | ||
| EP09160326 | 2009-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2011000016A true DOP2011000016A (es) | 2011-02-15 |
Family
ID=41073830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2011000016A DOP2011000016A (es) | 2008-07-17 | 2011-01-14 | Composiciones y metodos de uso para anticuerpos terapeuticos |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US8106163B2 (es) |
| EP (1) | EP2315780B8 (es) |
| JP (2) | JP5767109B2 (es) |
| KR (2) | KR101314369B1 (es) |
| CN (1) | CN102119174B (es) |
| AR (1) | AR072749A1 (es) |
| AU (1) | AU2009272771B2 (es) |
| BR (1) | BRPI0915928B8 (es) |
| CA (1) | CA2730063C (es) |
| CL (1) | CL2011000086A1 (es) |
| CR (1) | CR11863A (es) |
| CU (1) | CU23878B1 (es) |
| CY (1) | CY1116800T1 (es) |
| DK (1) | DK2315780T3 (es) |
| DO (1) | DOP2011000016A (es) |
| EA (1) | EA024492B1 (es) |
| EC (1) | ECSP11010761A (es) |
| ES (1) | ES2547270T3 (es) |
| GE (1) | GEP20146129B (es) |
| HR (1) | HRP20151227T1 (es) |
| HU (1) | HUE025778T2 (es) |
| IL (1) | IL210485A (es) |
| JO (1) | JO3149B1 (es) |
| MA (1) | MA32481B1 (es) |
| MX (1) | MX2011000616A (es) |
| MY (1) | MY158980A (es) |
| NI (1) | NI201100017A (es) |
| NZ (1) | NZ590057A (es) |
| PE (1) | PE20110563A1 (es) |
| PL (1) | PL2315780T3 (es) |
| PT (1) | PT2315780E (es) |
| RS (1) | RS54299B1 (es) |
| SG (1) | SG193805A1 (es) |
| SI (1) | SI2315780T1 (es) |
| SM (1) | SMP201100010B (es) |
| SV (1) | SV2011003807A (es) |
| TW (1) | TWI508742B (es) |
| UY (1) | UY31987A (es) |
| WO (1) | WO2010007082A1 (es) |
| ZA (1) | ZA201008952B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US20090176654A1 (en) * | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| US9458240B2 (en) * | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| JP2012153788A (ja) * | 2011-01-25 | 2012-08-16 | Nitto Denko Corp | 光学用粘着シート |
| NZ724296A (en) * | 2011-05-13 | 2020-05-29 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer expressing claudin 6 |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| US10435474B2 (en) | 2013-12-24 | 2019-10-08 | Ossianix, Inc. | Baff selective binding compounds and related methods |
| AU2015315834B2 (en) | 2014-01-31 | 2019-12-12 | Boehringer Ingelheim International Gmbh | Novel anti-BAFF antibodies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
| WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
| KR20180108651A (ko) | 2016-02-10 | 2018-10-04 | 노파르티스 아게 | 일차 쇼그렌 증후군의 치료를 위한 pi3k의 활성 또는 기능의 억제제의 용도 |
| CN116041514A (zh) * | 2016-06-06 | 2023-05-02 | 希望之城 | Baff-r抗体及其用途 |
| US11197928B2 (en) | 2017-01-13 | 2021-12-14 | Board Of Regents, The University Of Texas System | Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate |
| IL309444A (en) * | 2017-05-24 | 2024-02-01 | Als Therapy Development Inst | Therapeutic anti-cd40 ligand antibodies |
| IL271194B2 (en) * | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| MX2021000708A (es) * | 2018-07-20 | 2021-03-25 | Teneobio Inc | Anticuerpos de cadena pesada que se unen al cd19. |
| TWI859192B (zh) * | 2019-03-29 | 2024-10-21 | 日商中外製藥股份有限公司 | 包含抗il-6受體抗體之bbb功能低下之抑制劑 |
| CR20210576A (es) | 2019-05-21 | 2021-12-15 | Novartis Ag | Moléculas de unión a cd19 y usos de las mismas |
| KR20220093347A (ko) * | 2019-11-06 | 2022-07-05 | 노파르티스 아게 | 쇼그렌 증후군의 치료 |
| CN112813099A (zh) * | 2019-11-15 | 2021-05-18 | 上海细胞治疗集团有限公司 | 一种在活化的t细胞中具有高活性的启动子 |
| CN116133687A (zh) | 2020-08-04 | 2023-05-16 | 诺华股份有限公司 | B细胞恶性肿瘤的治疗 |
| TW202206103A (zh) | 2020-08-04 | 2022-02-16 | 瑞士商諾華公司 | Ｃｌｌ的治療 |
| CN118459585A (zh) * | 2020-09-07 | 2024-08-09 | 白先宏 | Baff-r结合分子及其应用 |
| US20250215081A1 (en) | 2020-11-06 | 2025-07-03 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
| CN115073598B (zh) * | 2021-03-15 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗baffr抗体及其应用 |
| JP2024516019A (ja) | 2021-05-04 | 2024-04-11 | ノバルティス アーゲー | 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療 |
| IL308045A (en) | 2021-05-04 | 2023-12-01 | Novartis Ag | Treatment of lupus nephritis using antibuffer antibodies |
| TW202440636A (zh) | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
| WO2025058962A1 (en) * | 2023-09-11 | 2025-03-20 | Absci Corporation | High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria |
| WO2025131888A1 (en) | 2023-12-19 | 2025-06-26 | Basf Se | Modified alkoxylated polyalkylene imines or modified alkoxylated polyamines |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS51157B (sr) * | 1999-08-17 | 2010-10-31 | Biogen Idec Ma Inc. | Baff receptor (bcma), imunoregulatorni agens |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| KR20070107687A (ko) * | 2004-12-31 | 2007-11-07 | 제넨테크, 인크. | Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도 |
| US20100166741A1 (en) * | 2006-07-13 | 2010-07-01 | Genentech , Inc. | Altered br-3 binding polypeptides |
-
2009
- 2009-07-15 KR KR1020117001052A patent/KR101314369B1/ko active Active
- 2009-07-15 MX MX2011000616A patent/MX2011000616A/es active IP Right Grant
- 2009-07-15 MY MYPI2010005960A patent/MY158980A/en unknown
- 2009-07-15 HU HUE09797499A patent/HUE025778T2/en unknown
- 2009-07-15 CN CN200980127408.2A patent/CN102119174B/zh active Active
- 2009-07-15 DK DK09797499.2T patent/DK2315780T3/en active
- 2009-07-15 PE PE2011000038A patent/PE20110563A1/es active IP Right Grant
- 2009-07-15 EA EA201100191A patent/EA024492B1/ru not_active IP Right Cessation
- 2009-07-15 AU AU2009272771A patent/AU2009272771B2/en active Active
- 2009-07-15 SI SI200931293T patent/SI2315780T1/sl unknown
- 2009-07-15 US US12/503,175 patent/US8106163B2/en active Active
- 2009-07-15 RS RS20150667A patent/RS54299B1/en unknown
- 2009-07-15 WO PCT/EP2009/059030 patent/WO2010007082A1/en active Application Filing
- 2009-07-15 BR BRPI0915928A patent/BRPI0915928B8/pt active IP Right Grant
- 2009-07-15 KR KR1020137019574A patent/KR101545795B1/ko active Active
- 2009-07-15 PL PL09797499T patent/PL2315780T3/pl unknown
- 2009-07-15 ES ES09797499.2T patent/ES2547270T3/es active Active
- 2009-07-15 PT PT97974992T patent/PT2315780E/pt unknown
- 2009-07-15 GE GEAP200912063A patent/GEP20146129B/en unknown
- 2009-07-15 SG SG2013062567A patent/SG193805A1/en unknown
- 2009-07-15 EP EP09797499.2A patent/EP2315780B8/en active Active
- 2009-07-15 UY UY0001031987A patent/UY31987A/es active IP Right Grant
- 2009-07-15 CA CA2730063A patent/CA2730063C/en active Active
- 2009-07-15 AR ARP090102678A patent/AR072749A1/es active IP Right Grant
- 2009-07-15 NZ NZ590057A patent/NZ590057A/xx unknown
- 2009-07-15 JP JP2011517915A patent/JP5767109B2/ja active Active
- 2009-07-15 HR HRP20151227TT patent/HRP20151227T1/hr unknown
- 2009-07-16 TW TW098124126A patent/TWI508742B/zh active
- 2009-07-16 JO JOP/2009/0267A patent/JO3149B1/ar active
-
2010
- 2010-12-13 ZA ZA2010/08952A patent/ZA201008952B/en unknown
- 2010-12-21 CR CR11863A patent/CR11863A/es unknown
-
2011
- 2011-01-06 IL IL210485A patent/IL210485A/en active IP Right Grant
- 2011-01-14 DO DO2011000016A patent/DOP2011000016A/es unknown
- 2011-01-14 MA MA33525A patent/MA32481B1/fr unknown
- 2011-01-14 NI NI201100017A patent/NI201100017A/es unknown
- 2011-01-14 CL CL2011000086A patent/CL2011000086A1/es unknown
- 2011-01-17 CU CUP2011000013A patent/CU23878B1/es active IP Right Grant
- 2011-01-17 SV SV2011003807A patent/SV2011003807A/es unknown
- 2011-01-17 EC EC2011010761A patent/ECSP11010761A/es unknown
- 2011-02-17 SM SM201100010T patent/SMP201100010B/it unknown
- 2011-12-15 US US13/326,569 patent/US9382326B2/en active Active
- 2011-12-15 US US13/326,514 patent/US9340620B2/en active Active
-
2015
- 2015-04-10 JP JP2015081099A patent/JP6077587B2/ja active Active
- 2015-10-19 CY CY20151100934T patent/CY1116800T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2011000016A (es) | Composiciones y metodos de uso para anticuerpos terapeuticos | |
| CL2008001632A1 (es) | Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma. | |
| CL2018000353A1 (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| CO6541572A2 (es) | Octahidropirrolo[3.4-c]pirrolos distituidos como moduladores del receptor de orexina | |
| CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
| GT201500294A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| CL2010001637A1 (es) | Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras. | |
| ECSP11010932A (es) | Compuestos de azaindazol como antagonistas del receptor de ccr1 | |
| CL2008001335A1 (es) | Compuestos derivados de pirrolopirimidin-7-ona, antagonistas de los receptores de purina p2x; porceso de preparacion de estos; composicion farmaceutica que los comprende; proceso de preparacion de compuestos intermediarios y usos en el tratamientos del dolor, vejiga hiperactiva, entre otras. | |
| UY33651A (es) | Anticuerpos anti-il12rbeta1 y su uso para tratar los trastornos autoinmunes e inflamatorios | |
| CL2010001641A1 (es) | Compuestos derivados de heterociclos biciclicos sustituidos; composicion farmaceutica; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas e inflamatorias tales como cancer y artritis reumatoide entre otras. | |
| MX2009006786A (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
| UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
| CL2015002202A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4. | |
| PE20170192A1 (es) | Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad | |
| EA201101572A1 (ru) | Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12 | |
| PE20170703A1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos | |
| CL2011001427A1 (es) | Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras. | |
| UY31340A1 (es) | Moduladores tieno- y furo-pirimidina del receptor de histamina h4 | |
| MX386470B (es) | Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite. | |
| GT200800052A (es) | Compuestos triciclicos utiles como agonistas de recepciones de oxitocina | |
| CL2012002541A1 (es) | Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros. | |
| CO6341571A2 (es) | Composiciones y metodos de uso para anticuerpos terapeuticos | |
| CL2011003076A1 (es) | Compuestos derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y su uso como inhibidores de la interaccion de las icam con las leucointegrinas y como antagonistas de lfa-1 para tratar una inflamacion o una afeccion inflamatoria tal como infarto al miocardio, accidente cerebrovascular, psoriasis, tiroiditis autoinmunitaria, enfermedad de crohn. |